ES2175901T3 - Benzoimidazoles como inhibidores de la cilooxigenasa-2. - Google Patents

Benzoimidazoles como inhibidores de la cilooxigenasa-2.

Info

Publication number
ES2175901T3
ES2175901T3 ES99300824T ES99300824T ES2175901T3 ES 2175901 T3 ES2175901 T3 ES 2175901T3 ES 99300824 T ES99300824 T ES 99300824T ES 99300824 T ES99300824 T ES 99300824T ES 2175901 T3 ES2175901 T3 ES 2175901T3
Authority
ES
Spain
Prior art keywords
alkyl
halo
heteroaryl
phenyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99300824T
Other languages
English (en)
Inventor
Yoshiyuki Okumura
Yoshinori Murata
Takashi Mano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2175901T3 publication Critical patent/ES2175901T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

EN ESTA INVENCION SE PRESENTA UN COMPUESTO DE LA FORMULA SIGUIENTE: O LAS SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO, EN LA QUE AR ES HETEROARILO; X 1 Y X 2 SE SELECCIONAN, INDEPENDIENTEMENTE, DE HALO, ALQUILO C 1 - C 4 , H IDROXI, ALCOXI C 1 - C 4 , AMINO, ALCANOILO C 1 - C 4 , CARBOXI, CARBAMILO, CIANO, NITRO, MERCAPTO, (ALQUIL)TIO C 1 - C 4 , (ALQUIL)SULFINILO C 1 C 4 , (ALQUIL)SULFONILO C 1 - C 4 , AMINOSULFONILO, O ANALOGOS; R 1 SE SELECCIONA DEL HIDROGENO, ALQUILO C 1 C 4 LINEAL O RAMIFICADO, CICLOALQUILO C 3 - C 8 , CICLOALQUENILO C 4 C 8 , FENILO, HETEROARILO Y SIMILARES; R 2 Y R 3 SE SELECCIONAN, INDEPENDIENTEMENTE, DEL HIDROGENO, HALO, ALQUILO C 1 - C 4 , FENILO Y ANALOGOS; O R 1 Y R 2 PUEDEN FORMAR, JUNTO CON EL ATOMO DE CARBONO AL QUE ESTAN ENLAZADOS, UN ANILLO DE CICLOALQUILO C5 C 7 ; Y M Y N SON, INDEPENDIENTEMENTE, 0, 1, 2 O 3. ESTOS COMPUESTOS Y LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES COMPUESTOS SON UTILES COMO AGENTES ANALGESICOS Y ANTIINFLAMATORIOS.
ES99300824T 1998-02-11 1999-02-04 Benzoimidazoles como inhibidores de la cilooxigenasa-2. Expired - Lifetime ES2175901T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9800164 1998-02-11
US09/244,875 US6310079B1 (en) 1998-02-11 1999-02-05 Benzimidazole cyclooxygenase-2 inhibitors

Publications (1)

Publication Number Publication Date
ES2175901T3 true ES2175901T3 (es) 2002-11-16

Family

ID=26318715

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99300824T Expired - Lifetime ES2175901T3 (es) 1998-02-11 1999-02-04 Benzoimidazoles como inhibidores de la cilooxigenasa-2.

Country Status (10)

Country Link
US (3) US6310079B1 (es)
EP (1) EP0937722B1 (es)
JP (1) JP3256513B2 (es)
AT (1) ATE220066T1 (es)
BR (1) BR9900565A (es)
CA (1) CA2261426C (es)
DE (1) DE69901969T2 (es)
DK (1) DK0937722T3 (es)
ES (1) ES2175901T3 (es)
PT (1) PT937722E (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
JP3256513B2 (ja) 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US20040102442A1 (en) * 2000-06-29 2004-05-27 Kohji Hanasaki Remedies for alzheimer's disease
TW583000B (en) * 2000-06-29 2004-04-11 Shionogi & Co X-type sPLA2 inhibitor as a cancer therapeutical agent
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
RU2296758C2 (ru) * 2002-08-08 2007-04-10 Смитклайн Бичем Корпорейшн Производные тиофена
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−２−δリガンド
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
ATE342722T1 (de) 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
PT1745791E (pt) 2003-05-07 2013-07-23 Osteologix As Tratamento de afeções cartilagíneas/ósseas com sais de estrôncio hidrossolúveis
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
WO2005075470A1 (en) 2004-01-28 2005-08-18 Smithkline Beecham Corporation Thiazole compounds
BRPI0510340A (pt) * 2004-04-28 2007-10-30 Pfizer derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina
CA2583667A1 (en) * 2004-10-12 2006-04-27 Jasbir Singh Sulfonamide peri-substituted bicyclics for occlusive artery disease
WO2006063466A1 (en) * 2004-12-17 2006-06-22 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors
US7442716B2 (en) * 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
AU2006244393B2 (en) * 2005-05-05 2012-06-21 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
JP2009530409A (ja) * 2006-03-23 2009-08-27 シンタ ファーマシューティカルズ コーポレーション 炎症及び免疫関連使用用のベンゾイミダゾリル−ピリジン化合物
WO2007124589A1 (en) * 2006-05-02 2007-11-08 Merck Frosst Canada Ltd. Methods for treating or preventing neoplasias
NZ574028A (en) 2006-07-05 2010-10-29 Fibrotech Therapeutics Pty Ltd Tranilast analogues (substituted cinnamoyl anthranilate compounds) for treatment of conditions associated with firbrosis
BRPI0720351A2 (pt) 2006-12-22 2019-05-14 Recordati Ireland Limited terapia de combinação para distúrbios do trato urinário inferior com ligantes a2o e aines.
WO2010012745A2 (en) * 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh Benzimidazoles
WO2011047432A1 (en) * 2009-10-22 2011-04-28 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
EP3577103A1 (en) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
CN111587292A (zh) * 2018-01-07 2020-08-25 纽克莱克斯有限公司 用于检测癌症相关突变的试剂盒和方法
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5013795B2 (es) 1972-12-12 1975-05-22
JPS5975257A (ja) 1982-10-23 1984-04-27 Ricoh Co Ltd 電子写真用感光体
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US4812460A (en) * 1986-03-25 1989-03-14 Boehringer Ingelheim Pharmaceutical, Inc. 3-[2-(3',5'-di-t-butyl-4'-hydroxyphenyl)ethenyl]pyridine
JPH06759B2 (ja) * 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
JPH03219232A (ja) 1990-01-24 1991-09-26 Konica Corp 分光増感されたハロゲン化銀写真感光材料
JPH06194780A (ja) 1992-12-24 1994-07-15 Konica Corp ハロゲン化銀写真乳剤
JP3219232B2 (ja) 1995-08-14 2001-10-15 シャープ株式会社 液晶表示装置
PT846689E (pt) * 1996-12-09 2004-06-30 Pfizer Compostos de benzimidazole
CA2280761A1 (en) 1997-02-13 1998-08-20 Stanley Dawes Chamberlain Benzimidazole derivatives
JP3256513B2 (ja) 1998-02-11 2002-02-12 ファイザー製薬株式会社 ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤

Also Published As

Publication number Publication date
US20040181062A1 (en) 2004-09-16
EP0937722A1 (en) 1999-08-25
EP0937722B1 (en) 2002-07-03
CA2261426A1 (en) 1999-08-11
PT937722E (pt) 2002-10-31
US6713482B2 (en) 2004-03-30
US6310079B1 (en) 2001-10-30
DE69901969D1 (de) 2002-08-08
DE69901969T2 (de) 2002-10-24
CA2261426C (en) 2002-09-24
ATE220066T1 (de) 2002-07-15
BR9900565A (pt) 2000-05-02
US20030013886A1 (en) 2003-01-16
JPH11263788A (ja) 1999-09-28
DK0937722T3 (da) 2002-07-22
JP3256513B2 (ja) 2002-02-12

Similar Documents

Publication Publication Date Title
ES2175901T3 (es) Benzoimidazoles como inhibidores de la cilooxigenasa-2.
DK1104760T3 (da) Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
IL160304A (en) Compounds and composition for activating peroxisome proliferators-responsive receptor ??
DE69418704D1 (de) Anthranilsäure derivate
PT976748E (pt) Derivados de pirrolidina com actividade inibidora de fosfolipase a2
AU686222B2 (en) Cyclodepsipeptide compound
DK1104759T3 (da) Heteroarylphenylpyrazolforbindelser som antiinflammatoriske/analgetiske midler
ID23954A (id) Tetrahidrogama-karbolin
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
ES2137158T3 (es) N-bencil-indoles, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AU2001228862A1 (en) Remedies or preventives for liver diseases containing diaminotrifluoromethylpyridine derivatives
IL151880A0 (en) Triazole derivatives and pharmaceutical compositions containing the same
DE60238847D1 (de) Pyrimidinderivate enthaltendes medikament
BR9305092A (pt) Processo para a preparação de derivados de 5-pirazolmercáptan, composto ditiocarbazato de etilideno, processo para a preparação de derivados do mesmo

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 937722

Country of ref document: ES